Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431747 | PMC |
| http://dx.doi.org/10.1038/s41415-020-2004-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: The treatment of aggressive behavior and agitation in pediatric patients with autism spectrum disorder (ASD) in the emergency department is topical and challenging.
Case Presentation: We described an adolescent with autism spectrum disorder treated ten times in the pediatric emergency department for severe episodes of aggressiveness and agitation. After resolving the acute phase of these behavioural crises, sedation was maintained with a continuous infusion of dexmedetomidine to prevent the resurgence of agitation and to organize discharge properly, considering the family's needs.
The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders.
Pharmacol Biochem Behav
February 2022
Laboratory of Antiepileptic Drug Discovery, Ascension St. Vincent, Indianapolis, IN, USA; RespireRx Pharmaceuticals Inc., Glen Rock, NJ, USA; Department of Anatomy and Cell Biology, Indiana University/Purdue University, Indianapolis, IN, USA; Faculty of Medicine, University of Ljubljana, Zaloška cesta 4, Ljubljana, Slovenia. Electronic address:
Article Synopsis
- GABAkines are positive allosteric modulators of GABA receptors, used to treat conditions like anxiety, epilepsy, and sleep disorders; however, the development of new GABAkines had slowed down due to safety and side-effect concerns.
- Recently, there has been renewed interest and progress in bringing new GABAkines to market, with the FDA approving brexanolone for post-partum depression in 2019 and several others currently in clinical development.
- KRM-II-81 is highlighted as a promising new GABAkine with potential effectiveness against pharmacoresistant epilepsy, traumatic brain injury, and neuropathic pain, showing low sedation, no tolerance development, and anxiolytic and antidepressant-like
Implementation of a spinal anesthesia and sedation protocol that reliably prolongs infant spinal anesthesia: Case series of 102 infants who received spinal anesthesia for urologic surgery.
Paediatr Anaesth
December 2020
Department of Perioperative Medicine and Anesthesia, Mayo Clinic, Rochester, MN, USA.
Background: The use of spinal anesthesia in infants is seeing resurgence as an alternative to general anesthesia.
Aims: Our primary aims are to describe our institution's experience introducing a spinal anesthesia and sedation protocol for infants undergoing urologic surgery, to describe methods of improving prolonged anesthesia, and to describe the failure rate of spinal anesthesia in these patients. Sedation was provided for some infants with intranasal dexmedetomidine ± fentanyl.
Methoxyflurane for Procedural Analgesia at 4470 m Altitude.
Wilderness Environ Med
September 2018
Royal Gwent Hospital, Newport, United Kingdom (Dr Mason); International Porter Protection Group, Cardiff, United Kingdom (Dr Mason).
Methoxyflurane is a volatile, fluorinated anesthetic agent with analgesic properties. Although no longer used as an anesthetic due to concerns regarding renal toxicity in high doses, it has enjoyed a resurgence as an inhaled analgesic in prehospital care and in the emergency department. The agent is nonflammable and leads to rapid, titratable analgesia without intravenous access.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!